Currently used drug administration routes suffer from several drawbacks that hinder the efficacy of therapeutics, including drug breakdown by the body, substantial systemic side effects, and high drug toxicity that restricts the drug dosage that can be used. Bio-Path Holdings has developed a powerful drug delivery technology that utilizes cell-like drug carriers, termed liposomes, which avoid drug breakdown, vastly decreases systemic side effects, lowers drug toxicity enabling higher dosages to be used and increases bioavailability to improve drug efficacy, all of which circumvent currently seen drug delivery limitations.
The company’s primary drug candidate uses its drug delivery system in conjunction with their anti-sense nucleic acid cancer therapeutic which is currently in Phase I clinical trials indicated for treatment of various forms of Leukemia and Myelodysplastic Syndrome. The company’s good working relationship with the MD Anderson Cancer Center and its out-license oriented strategy should build shareholder value in a rapid and cost-effective way.
Bio-Path Holdings, a OneMedForum NY 2011 presenting company, recently announced that Dr. Ana Maria Tari, PhD, MBA has been appointed Director of Preclinical Operations and Research. She will report to Peter Nielsen, President and Chief Executive Officer and be responsible for leading the company’s evaluation and selection of new drug targets for licensing and development; design, source and direct preclinical in vitro and in vivo studies; and be the primary scientific liaison to the scientific community and clinical trial sites, including University of Texas MD Anderson Cancer Center.